Scholars Central

Conference abstractPublished 7 Jul 2025

Pancreatic Neuroendocrine Tumours (PanNETs)

Authors: Kamran Nazir

Lancashire Teaching Hospital, UK

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Pancreatic neuroendocrine tumours (PanNETs) are a rare subset of pancreatic neoplasms arising from islet cells, comprising 2-5% of all pancreatic tumours. These tumours exhibit heterogeneous clinical behaviour and may be functioning (hormone-producing) or non-functioning. Though many cases are sporadic, PanNETs may also occur in the context of hereditary syndromes such as Multiple Endocrine Neoplasia type 1 (MEN1), Von Hippel-Lindau (VHL), and Neurofibromatosis type 1 (NF1). Types: Functioning PanNETs are classified based on the predominant hormone secreted, including insulinomas, Gastrinoma, glucagonomas, VIPoma, and Somatostatinoma. Non-functioning PanNETs, which do not produce a clinical hormone syndrome, are often diagnosed incidentally or at an advanced stage. Diagnosis: Diagnostic work-up includes hormonal assays (e.g., insulin, gastrin, chromogranin A), imaging (CT, MRI), and functional nuclear imaging with Ga-68 DOTATATE PET/CT. Histopathological confirmation with immunohistochemistry (e.g., synaptophysin, chromogranin) and grading using Ki-67 index are essential for prognostication. Management: For localized disease, surgical resection offers the best chance for cure. In metastatic or unresectable cases, somatostatin analogues (e.g., octreotide, Lanreotide) are used to control symptoms and Tumour progression. Targeted therapies such as Everolimus and sunitinib have shown efficacy in progressive disease. Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE is another promising option for somatostatin receptor–positive tumours. Chemotherapy (e.g., streptozocin, temozolomide) may be considered for high-grade or rapidly progressive tumours. Conclusion: PanNETs are complex tumours requiring individualized, multidisciplinary care. While prognosis is generally better than for pancreatic adenocarcinoma, outcomes depend on tumour grade, stage, and responsiveness to therapy. Advances in imaging and targeted treatments have significantly improved management and survival in recent years.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Kamran Nazir”